šĀ·14h agodiscovery
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Publisher
A
AstraZeneca
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AstraZeneca
- Region
- Global
- Scope
- discovery
- Published
- July 27, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: AstraZeneca
Scope: discovery
Related coverage
More related coverage
marketscreener.com/4h ago
Legend Biotech Shares Fall After CEO Huang Resigns
Hartford Business Journal/4h ago
Branford-based biotech Quantum-Si at risk of Nasdaq delisting, again
simplywall.st/4h ago
AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus
U.S. News & World Report/4h ago